ArticleArthritis & rheumatology (Hoboken, N.J.)2022

Predictors of Rheumatic Immune-Related Adverse Events and De Novo Inflammatory Arthritis After Immune Checkpoint Inhibitor Treatment for Cancer.

Amy Cunningham-Bussel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.